Caspofungin: Antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 4, 2006, Pages 732-740

  van Vianen, Wim ^a   de Marie, Siem ^a   ten Kate, Marian T ^a   Mathot, Ron A A ^a   Bakker Woudenberg, Irma A J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Amphotericin B; Aspergillus fumigatus; Galactomannan; Quantitative PCR; XTT assay

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; CASPOFUNGIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; FUNGAL DNA; GALACTOMANNAN; POLYMYXIN B; TEICOPLANIN; TETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS FUMIGATUS; BIOASSAY; BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION FUNCTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG SENSITIVITY; FUNGUS GROWTH; IN VITRO STUDY; INOCULATION; LUNG ASPERGILLOSIS; LUNG PARENCHYMA; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; SURVIVAL RATE; SURVIVAL TIME;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DISEASE MODELS, ANIMAL; HUMANS; LUNG; LUNG DISEASES, FUNGAL; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; PEPTIDES, CYCLIC; RATS; TREATMENT OUTCOME;

EID: 33645113982     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl015     Document Type: Article

References (33)

1. Letcher-Bru V. Caspofungin: The first representative of a new antifungal class. J Antimicrob Chemother 2003; 51: 513-21.
2. Groll AH, Shah PM, Mentzel C et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23-32.
3. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445-57.
4. Maertens J, Glasmacher A, Selleslag D et al. Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: Results from the caspofungin invasive aspergillus study. Clin Infect Dis 2005; 41: E9-14.
5. Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988; 148: 2389-94.
6. Warnock, DW. Amphotericin B: An introduction. J Antimicrob Chemother 1991; 28: 27-38.
7. Herbrecht, R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
8. Sable CA, Nguyen BYT, Chodakewitz JA et al. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002; 4: 25-30.
9. Lewis RE, Wiederhold NP, Klepser ME. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicrob Agents Chemother 2005; 49: 945-51.
10. Meletiadis J, Mouton JW, Meis JFG et al. Eurofung network. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2001; 39: 3402-8.
11. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Approved Standard M38-A. CLSI, Wayne, PA, USA, 2005.
12. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-71.
13. Abruzzo GK, Gill CJ, Flatterly AM et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 2000; 44: 2310-18.
14. Bowman JC, Abruzzo GK, Anderson JW et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: Demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001; 45: 3474-81.
15. Imai J, Singh G, Fernandez B et al. Efficacy of Abelcet and Caspofungin, alone or in combination, against CNS aspergillosis in a murine model. J Antimicrob Chemother 2005; 56: 166-71.
16. Kirkpatrick WR, Perea S, Coco BJ et al. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564-68.
17. Petraitiene R, Petraitis V, Groll AH et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: Pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46: 12-23.
18. Wiederhold NP, Kontoyiannis DP, Jingduan C et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464-71.
19. Becker MJ, de Marie S, Fens MHAM et al. Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 2003; 52: 428-34.
20. Becker MJ, de Marie S, Willemse D et al. Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model. J Clin Microbiol 2000; 38: 1434-8.
21. Arikan S, Lozano-Chiu M, Paetznick V et al. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001; 45: 327-30.
22. Bowman JC, Hicks PS, Kurtz MB et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46: 3001-12.
23. Arikan S, Lozano-Chiu M, Paetznick V et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: 245-7.
24. Kuhn DM, Balkis M, Chandra J et al. Uses and limitations of the XTT assay in studies of candida growth metabolism. J Clin Microbiol 2003; 41: 506-8.
25. Becker MJ, Dams EThM, de Marie S et al. Scintigraphic imaging using 99mTc-labeled PEG liposomes allows early detection of experimental invasive pulmonary aspergillosis in neutropenic rats. Nucl Med Biol 2002; 29: 177-84.
26. Walsh TJ, McEntee C, Dixon DM. Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans. J Clin Microbiol 1987; 25: 931-2.
27. Ibrahim AS, Bowman JC, Avanessian V et al. Caspofungin inhibits Rhizopus oryzae 1,3-β-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2004; 49: 721-7.
28. Andes D. Clinical utility of antifungal pharmacokinetics and pharmacodynamics. Curr Opin Infect Dis 2004; 17: 533-40.
29. Hajdu R, Thompson R, Sundelof JG et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2339-44.
30. Sandhu, P, Xu X, Bondiskey PJ et al. Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother 2004; 48: 1272-80.
31. Stone JA, Xu X, Winchell GA et al. Disposition of caspofungin: Role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004; 48: 815-23.
32. Stone JA, Holland SD, Wickersham PJ et al. Single- and Multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46: 739-45.
33. Bekersky I, Fielding RM, Dressler DE et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002; 46: 828-33.